The COLEC11 antibody targets the protein encoded by the COLEC11 gene, a member of the collectin family involved in innate immunity. Collectins are pattern recognition molecules characterized by collagen-like domains and carbohydrate recognition domains (CRDs), which bind pathogen-associated molecular patterns (PAMPs) or apoptotic cells, facilitating immune clearance. COLEC11. also known as collectin kidney 1 (CL-K1), is synthesized in the liver, kidneys, and epithelial tissues. It plays roles in complement activation, inflammation modulation, and tissue homeostasis.
Mutations in COLEC11 are linked to 3MC syndrome, a rare autosomal recessive disorder causing developmental anomalies (e.g., craniofacial, skeletal). COLEC11 antibodies are utilized in research to study its expression, localization, and interactions in immune pathways or disease models. They are also explored as diagnostic tools for 3MC syndrome and in understanding COLEC11's involvement in conditions like fibrosis or cancer. Commercial COLEC11 antibodies are available for techniques such as Western blotting, immunohistochemistry, and ELISA.
Recent studies highlight its dual role in host defense and tissue repair, making it a potential therapeutic target. However, standardized antibody validation remains critical due to variability in specificity across commercial sources. Research continues to elucidate COLEC11's mechanisms in immunity and disease.